Abstract
Background: Stroke is the second leading cause of death worldwide. Understanding of gene expression dynamics could bring new approaches in diagnostics and therapy of stroke. Small noncoding molecules termed “microRNA” represent the most flexible network of gene expression regulators.
Method: The aim of this review was to briefly describe the structure and function of microRNA and summarize the current knowledge about the involvement of microRNAs in the pathophysiology of ischemic and hemorrhagic stroke based on both experimental and clinical studies. Results: Numerous profiling studies identified candidate microRNAs and partially described dynamics of their expression after the stroke. However, complex associations of specific microRNAs expression with main clinical characteristics and deeper insight into mechanisms of their regulatory functions are still missing. In this review, we put special emphasis on several microRNA clusters involved in neuroprotection (miR-124, miR-181, miR-21, miR-29, miR-210 and let7). Potential application of microRNAs as biomarkers and diagnostic or therapeutic targets was also discussed. Conclusion: Full understanding of the regulatory mechanisms of the microRNA networks represents a novel direction for stroke research. To date, we do not have effective tools to control pathophysiological processes associated with stroke. Thus the microRNAs have to be considered as a very promising target for future stroke therapies.Keywords: Central nervous system, embolectomies, hemorrgahic stroke, ischemic stroke, microRNA, thrombolysis.
Current Drug Delivery
Title:The Role of microRNA in Ischemic and Hemorrhagic Stroke
Volume: 14 Issue: 6
Author(s): Lipkova Jolana and Duris Kamil*
Affiliation:
- Institute of Pathological Physiology, Faculty of Medicine, Masaryk University Brno, Kamenice 5, 625 00 Brno,Czech Republic
Keywords: Central nervous system, embolectomies, hemorrgahic stroke, ischemic stroke, microRNA, thrombolysis.
Abstract: Background: Stroke is the second leading cause of death worldwide. Understanding of gene expression dynamics could bring new approaches in diagnostics and therapy of stroke. Small noncoding molecules termed “microRNA” represent the most flexible network of gene expression regulators.
Method: The aim of this review was to briefly describe the structure and function of microRNA and summarize the current knowledge about the involvement of microRNAs in the pathophysiology of ischemic and hemorrhagic stroke based on both experimental and clinical studies. Results: Numerous profiling studies identified candidate microRNAs and partially described dynamics of their expression after the stroke. However, complex associations of specific microRNAs expression with main clinical characteristics and deeper insight into mechanisms of their regulatory functions are still missing. In this review, we put special emphasis on several microRNA clusters involved in neuroprotection (miR-124, miR-181, miR-21, miR-29, miR-210 and let7). Potential application of microRNAs as biomarkers and diagnostic or therapeutic targets was also discussed. Conclusion: Full understanding of the regulatory mechanisms of the microRNA networks represents a novel direction for stroke research. To date, we do not have effective tools to control pathophysiological processes associated with stroke. Thus the microRNAs have to be considered as a very promising target for future stroke therapies.Export Options
About this article
Cite this article as:
Jolana Lipkova and Kamil Duris *, The Role of microRNA in Ischemic and Hemorrhagic Stroke, Current Drug Delivery 2017; 14 (6) . https://dx.doi.org/10.2174/1567201813666160919142212
DOI https://dx.doi.org/10.2174/1567201813666160919142212 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations
Current Pharmaceutical Design Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design A Feature-Free 30-Disease Pathological Brain Detection System by Linear Regression Classifier
CNS & Neurological Disorders - Drug Targets Novel Application of Plasma Treatment for Pharmaceutical and Biomedical Engineering
Current Drug Discovery Technologies Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology The Fetal Cardiac Function
Current Cardiology Reviews HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research Meet Our Section Editor
Central Nervous System Agents in Medicinal Chemistry BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design bmp3 is Required for Integrity of Blood Brain Barrier by Promoting Pericyte Coverage in Zebrafish Embryos
Current Molecular Medicine Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Role of Chitosan Biomaterials in Drug Delivery Systems: A Patent Perspective
Recent Patents on Materials Science Antiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management
Current Neuropharmacology Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry Antiepileptic Treatment Strategy in Vascular Malformations
Current Pharmaceutical Design Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Prevention of Intracerebral Haemorrhage
Current Drug Targets Intracranial Aneurysms; In Need of Early Diagnostic and Treatment Using Bio- and Nanotechnology
Current Medicinal Chemistry A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research